THE IMPACT OF FREMANEZUMAB ON MIGRAINE-SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN CHRONIC MIGRAINE PATIENTS WITH CONCOMITANT PREVENTIVE MEDICATION USE

被引：0
|
作者：
Lipton, R. B. [1 ,2 ]
Fitzgerald, T. [3 ]
Cohen, J. M. [3 ]
Gandhi, S. K. [3 ]
机构：
[1] Albert Einstein Coll Med, New York, NY USA
[2] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA
[3] Teva Pharmaceut, Frazer, PA USA
来源：
CEPHALALGIA | 2018年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
MTIS2018-1
引用
收藏
页码：95 / 96
页数：2
相关论文
共 50 条
  • [21] The Impact of Fremanezumab on Medication Overuse in Patients with Chronic Migraine
    Silberstein, S. D.
    Ashina, S.
    Katsarava, Z.
    Bibeau, K.
    Seminerio, M. J.
    Harlow, D.
    Cohen, J. M.
    HEADACHE, 2018, 58 : 76 - 77
  • [22] The Impact of Fremanezumab on Medication Overuse in Patients with Chronic Migraine
    Silberstein, Stephen D.
    Cohen, Joshua M.
    Bibeau, Kristen
    Seminerio, Michael J.
    ANNALS OF NEUROLOGY, 2018, 84 : S84 - S85
  • [23] The impact of fremanezumab on medication overuse in patients with chronic migraine
    Silberstein, Stephen D.
    Ashina, Sait
    Katsarava, Zaza
    Bibeau, Kristen
    Seminerio, Michael J.
    Harlow, Danielle E.
    Cohen, Joshua M.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [24] The Impact of Fremanezumab on Medication Overuse in patients With Chronic Migraine
    Silberstein, Stephen
    Ashina, Sait
    Katsarava, Zaza
    Bibeau, Kristen
    Seminerio, Michael
    Harlow, Danielle
    Cohen, Joshua
    NEUROLOGY, 2019, 92 (15)
  • [25] BURDEN OF COMORBID DEPRESSION AND ANXIETY ON MIGRAINE-SPECIFIC HEALTH-RELATED QUALITY OF LIFE AND WORK PRODUCTIVITY IN ADULT MIGRAINE PATIENTS IN THE UNITED STATES
    Lipton, Richard B.
    Iyer, Ravi
    Cohen, Joshua M.
    Jackson, James
    Campos, Verena Ramirez
    Cotton, Sarah
    Milligan, Gary
    Buse, Dawn C.
    CEPHALALGIA, 2020, 40 : 101 - 102
  • [26] Impact of Fremanezumab on Response Rates, Migraine Days, and Acute Medication Use in Patients with Chronic Migraine Who Have Failed at Least One Prior Migraine Preventive Medication
    Silberstein, Stephen
    Ailani, Jessica
    Cohen, Joshua
    Yang, Ronghua
    Yeung, Paul P.
    Campos, Verena Ramirez
    NEUROLOGY, 2019, 92 (15)
  • [27] Impact of fremanezumab on response rates, migraine days, and acute medication use in patients with chronic migraine who have failed at least one prior migraine preventive medication
    Silberstein, Stephen D.
    Ailani, Jessica
    Cohen, Joshua M.
    Yang, Ronghua
    Yeung, Paul P.
    Ramirez Campos, Verena
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [28] The impact of topiramate on health-related quality of life indicators in chronic migraine
    Dodick, David W.
    Silberstein, Stephen
    Saper, Joel
    Freitag, Fred G.
    Cady, Roger K.
    Rapoport, Alan M.
    Mathew, Ninan T.
    Hulihan, Joseph
    Crivera, Concetta
    Rupnow, Marcia F. T.
    Mao, Lian
    Finlayson, Gary
    Greenberg, Steven J.
    HEADACHE, 2007, 47 (10): : 1398 - 1408
  • [29] Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab
    Buse, Dawn C.
    Lipton, Richard B.
    Hallstrom, Yngve
    Reuter, Uwe
    Tepper, Stewart J.
    Zhang, Feng
    Sapra, Sandhya
    Picard, Hernan
    Mikol, Daniel D.
    Lenz, Robert A.
    CEPHALALGIA, 2018, 38 (10) : 1622 - 1631
  • [30] Determinants of migraine-specific quality of life
    Santanello, N
    Davies, G
    Allen, C
    Kramer, M
    Lipton, R
    CEPHALALGIA, 2002, 22 (08) : 680 - 685
12345